Discovery of a novel Coumarin-Dihydroquinoxalone derivative MY-673 as a tubulin polymerization inhibitor capable of inhibiting the ERK pathway with potent anti-gastric cancer activities.

[1]  Jianjun Chen,et al.  Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects. , 2022, Journal of medicinal chemistry.

[2]  Tingting Du,et al.  Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site. , 2022, Journal of medicinal chemistry.

[3]  Yuan-zheng Xia,et al.  Discovery of Novel N-Heterocyclic-Fused Deoxypodophyllotoxin Analogues as Tubulin Polymerization Inhibitors Targeting the Colchicine-Binding Site for Cancer Treatment. , 2022, Journal of medicinal chemistry.

[4]  Duane D. Miller,et al.  SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis. , 2022, Cancer letters.

[5]  M. Hawash.  Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy , 2022, Biomolecules.

[6]  A. Coluccia,et al.  Induction of Ferroptosis in Glioblastoma and Ovarian Cancers by a New Pyrrole Tubulin Assembly Inhibitor , 2022, Journal of medicinal chemistry.

[7]  Dong-Hua Yang,et al.  Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects. , 2022, Journal of medicinal chemistry.

[8]  Sheng-Hui Wang,et al.  Discovery of N-benzylarylamide derivatives as novel tubulin polymerization inhibitors capable of activating the Hippo pathway. , 2022, European journal of medicinal chemistry.

[9]  Ting Zhu,et al.  Discovery of novel coumarin-indole derivatives as tubulin polymerization inhibitors with potent anti-gastric cancer activities. , 2022, European journal of medicinal chemistry.

[10]  Junyi Liu,et al.  Discovery of (2-(pyrrolidin-1-yl)thieno[3,2-d]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone as a novel potent tubulin depolymerizing and vascular disrupting agent. , 2022, European journal of medicinal chemistry.

[11]  Shuang‐Xi Gu,et al.  Indole derivatives as tubulin polymerization inhibitors for the development of promising anticancer agents. , 2021, Bioorganic & medicinal chemistry.

[12]  Ping Chen,et al.  Design, synthesis and evaluation of novel bis-substituted aromatic amide dithiocarbamate derivatives as colchicine site tubulin polymerization inhibitors with potent anticancer activities. , 2021, European journal of medicinal chemistry.

[13]  Duane D. Miller,et al.  X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor. , 2021, Journal of medicinal chemistry.

[14]  Zhenpeng Guo,et al.  Design, synthesis and bioevaluation of 2,7-diaryl-pyrazolo[1,5-a]pyrimidines as tubulin polymerization inhibitors. , 2021, Bioorganic chemistry (Print).

[15]  K. Ding,et al.  Bifunctional chiral selenium-containing 1,4-diarylazetidin-2-ones with potent antitumor activities by disrupting tubulin polymerization and inducing reactive oxygen species production. , 2021, European journal of medicinal chemistry.

[16]  Ruo-Jun Man,et al.  A novel series of benzothiazepine derivatives as tubulin polymerization inhibitors with anti-tumor potency. , 2021, Bioorganic chemistry (Print).

[17]  Y. Assaraf,et al.  Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[18]  Guangcheng Wang,et al.  Design, synthesis and biological evaluation of novel thiazole-naphthalene derivatives as potential anticancer agents and tubulin polymerisation inhibitors , 2021, Journal of enzyme inhibition and medicinal chemistry.

[19]  Heba S. A. Elzahabi,et al.  Discovery of new quinolines as potent colchicine binding site inhibitors: design, synthesis, docking studies, and anti-proliferative evaluation , 2021, Journal of enzyme inhibition and medicinal chemistry.

[20]  Dongjun Fu,et al.  Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents in vitro via inhibiting tubulin polymerization and activating the Hippo signaling pathway. , 2020, European journal of medicinal chemistry.

[21]  Qiu Li,et al.  Synthesis and biological evaluation of benzofuran-based 3,4,5-trimethoxybenzamide derivatives as novel tubulin polymerization inhibitors. , 2020, Bioorganic chemistry.

[22]  N. O’Boyle,et al.  Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review , 2020, Pharmaceuticals.

[23]  K. Lee,et al.  Scaffold Hopping-Driven Optimization of 4-(Quinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-ones as Novel Tubulin Inhibitors. , 2019, ACS Medicinal Chemistry Letters.

[24]  F. Uckun,et al.  A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia , 2019, Cancers.

[25]  Cheng-Mei Zhang,et al.  The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo. , 2019, European journal of medicinal chemistry.

[26]  J. Tuszynski,et al.  Tubulin: Structure, Functions and Roles in Disease , 2019, Cells.

[27]  Naresh Dumala,et al.  Design, synthesis, biological and in silico evaluation of coumarin-hydrazone derivatives as tubulin targeted antiproliferative agents. , 2019, Bioorganic chemistry.

[28]  A. L. Risinger,et al.  Microtubule-Targeting Drugs: More than Antimitotics. , 2019, Journal of natural products.

[29]  Y. Ilan.  Microtubules: From understanding their dynamics to using them as potential therapeutic targets , 2018, Journal of cellular physiology.

[30]  K. Lee,et al.  In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents. , 2017, Journal of medicinal chemistry.

[31]  B. Kumar,et al.  Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials. , 2017, Current Cancer Drug Targets.

[32]  K. Chibale,et al.  Synthesis and biological evaluation of 4 arylcoumarin analogues as tubulin-targeting antitumor agents. , 2017, Bioorganic & medicinal chemistry.

[33]  Chunyu Wang,et al.  Design, Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 4-Substituted Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors. , 2016, Journal of medicinal chemistry.

[34]  Jinhui Hu,et al.  A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells. , 2015, Biochemical pharmacology.

[35]  Duane D. Miller,et al.  An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site , 2012, Pharmaceutical Research.

[36]  Richard A. Stanton,et al.  Drugs that target dynamic microtubules: A new molecular perspective , 2011, Medicinal research reviews.

[37]  Philippe P Roux,et al.  Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases , 2011, Microbiology and Molecular Reviews.

[38]  V. Bourgarel-Rey,et al.  Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2. , 2003, Journal of medicinal chemistry.

[39]  C. Dumontet,et al.  Microtubule-binding agents: a dynamic field of cancer therapeutics , 2010, Nature Reviews Drug Discovery.

[40]  G. Koren,et al.  Colchicine poisoning: the dark side of an ancient drug , 2010, Clinical toxicology.

[41]  M. Kavallaris.  Microtubules and resistance to tubulin-binding agents , 2010, Nature Reviews Cancer.

[42]  F. Giles,et al.  Microtubule dynamics as a target in oncology. , 2009, Cancer treatment reviews.

[43]  Liedewij Laan,et al.  Assembly dynamics of microtubules at molecular resolution , 2006, Nature.

[44]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[45]  Patrick A. Curmi,et al.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain , 2004, Nature.